AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer | Company Announcement

Investegate announcements from AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

Related Keywords

United States ,American ,Thomask Equels ,Robert Edwards ,Facebook ,University Of Pittsburgh Medical Center ,Gynecology Reproductive Sciences ,Linkedin ,Gynecologic Oncology Research At Magee Womens Hospital ,Exchange Commission ,Immunotech Inc ,Department Of Obstetrics ,Tech Announces Positive Top Line ,Protocol Planned Interim Report Data ,Ampligen Combined ,Recurrent Ovarian ,Immune Checkpoint Blockade ,Pittsburgh Medical Center ,Objective Response Rate ,Clinical Benefit Rate ,Progression Free Survival ,Reproductive Sciences ,Gynecologic Oncology Research ,Magee Womens Hospital ,Executive Officer Thomas ,Private Securities Litigation Reform Act ,Announcements ,Nvestegate Alerts ,K Wire ,Uk News ,Ews Alerts ,Mail News Alerts ,Tse News Alerts ,Tse Email Alerts ,Echmark Announcements ,Tse ,Regulatory News ,Ns Announcements ,Quities ,Quity News ,Quity Announcements ,Company News ,Hares ,Corporate News ,Orporate Financial News ,Orporate News Releases ,Orporate Finance News ,Usiness News ,